Zohreh Amoozgar

Harvard University — United States

Medicine · Health Sciences

36h-index7.9kcitations164works1.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Peptidase Inhibition and Analysis(52), Cholangiocarcinoma and Gallbladder Cancer Studies(48), Pancreatic and Hepatic Oncology Research(45), Cancer Immunotherapy and Biomarkers(35), Immune cells in cancer(26)

Publications164 total

TMIC-109. Wnt inhibition improves the efficacy of anti-PD-1 therapy in glioblastoma
Neuro-Oncology·2025Open Access
Targeting EPHB2/ABL1 restores anti-tumor immunity in a preclinical model of ependymoma 2418
The Journal of Immunology·2025Open Access
Wnt inhibition alleviates resistance to anti-PD1 therapy and improves antitumor immunity in glioblastoma
Proceedings of the National Academy of Sciences·2025· 3 citedOpen Access
Tumor microenvironment responsive TPZ-loaded core-shell polymeric nanoparticles for selective cancer bioreductive therapy
Advanced Pharmaceutical Bulletin·2025Open Access
Therapeutic and prognostic values of ferroptosis signature in glioblastoma
International Immunopharmacology·2025· 2 cited
Single cell RNA sequencing improves the next generation of approaches to AML treatment: challenges and perspectives
Molecular Medicine·2025· 7 citedOpen Access
Targeting EPHB2/ABL1 restores antitumor immunity in preclinical models of ependymoma
Proceedings of the National Academy of Sciences·2025· 4 citedOpen Access
Abstract B015: Wnt inhibition improves the efficacy of anti-PD-1 therapy in glioblastoma
Cancer Immunology Research·2024· 2 cited
EPEN-09. TARGETING EPHB2/ABL1 RESTORES ANTI-TUMOR IMMUNITY IN A PRECLINICAL MODEL OF EPENDYMOMA
Neuro-Oncology·2024Open Access
Supplementary Fig. S8 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy
2024Open Access
Supplementary Data from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy
2024Open Access
Supplementary Fig. S11 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy
2024Open Access
Supplementary Fig. S4 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy
2024Open Access
Supplementary Fig. S8 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy
2024Open Access
Data from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy
2024Open Access
Supplementary Fig. S12 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy
2024Open Access
Supplementary Fig. S7 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy
2024Open Access
Supplementary Fig. S9 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy
2024Open Access
Supplementary Fig. S12 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy
2024Open Access
Supplementary Fig. S6 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy
2024Open Access
page 1 of 9Next →

Frequent Co-authors

Rakesh K. Jain(16), Dai Fukumura(14), Dan G. Duda(11), Sylvie Roberge(7), Michael S. Goldberg(6), Yoon Yeo(6), Meenal Datta(6), Peigen Huang(6), Rana Jahanban‐Esfahlan(6), Jonas Kloepper(5), Lei Xu(5), Khaled Seidi(5), Mehdi Jaymand(5), Tahereh Javaheri(5), Ana Batista(4), Gino B. Ferraro(4), Jessica M. Posada(4), Sampurna Chatterjee(4), Joonyoung Park(4), Ashwin S. Kumar(4)